Fundraising FoxVersant Ventures — 2017 Investments
9 investments dated 2017 · listed companies and verified rows first · show all
Nouscom is a biotech company whose investors page lists its venture capital backers.
BiotechHealthtech
Riccardo Cortese(Co-Founder)Marina Udier(Chief Executive Officer and Board Director)Elisa Scarselli(Chief Scientific Officer and Co-Founder)Alfredo Nicosia(Co-founder)Antonella Folgori(Co-founder)Stefano Colloca(Co-founder)
Co-investors5AM VenturesAndera PartnersAngelini VenturesRevelation PartnersXGEN VentureBpifrance+6 more
Jnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins.
AI & Machine LearningBiotechDeep TechAustin, US
Joanne Dove Kotz(Founder)inJoel Barrish(Chief Scientific Officer)Donald W. Nicholson(Director)Matthew Hammond(Director)Caroline Stark Beer(Chief Business Officer)Carlo Rizzuto(Director)
Board seatCarlo Rizzuto· per SEC Form D
Co-investorsAvalon BioVenturesBain Capital Life SciencesPfizer Venture InvestmentsRA CapitalPfizer VenturesPolaris Partners
Developing ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor combination for complicated urinary tract infections.
BiotechMalvern, US
Christopher J. Burns(Executive Officer, Director)Daniel C. Pevear(Executive Officer)Michael Diem(Director)Vincent J. Milano(Director)Ezra Felker(Executive Officer)Shelley Chu(Director)
Board seatCarlo Rizzuto· per SEC Form D · $47.1M raise · filed Nov 2018
Co-investorsAMR Action FundBioAdvanceForesite Capital
Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma.
BiotechDeep TechHealthtechSan Carlos, US
Wayne(CEO)Rachel(VP of Operations)
Co-investorsBay City CapitalGV (Google Ventures)LAVLilly Asia VenturesAlexandriaFrazier Healthcare Partners+1 more
Metavention is developing a treatment that targets the sympathetic nervous system to disrupt overactive nerves believed to contribute to high blood pressure and other metabolic diseases.
BiotechHealthtechMedical DevicesEden Prairie, US
Bobak Azamian(Executive Officer, Director)Tony Vrba(Executive Officer)Kevin Hykes(Executive Officer, Director)Kirk Nielsen(Director)in
Co-investorsSanderling VenturesNew Enterprise Associates (NEA)Vensana Capital
Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.
AI & Machine LearningBiotechDeep TechPrinceton, US
Ben Cravatt(Scientific Founder)Phil Baran(Scientific Founder)Jin-Quan Yu(Scientific Founder)Aleksandra Rizo(President and Chief Executive Officer)in
BoardJohn Park(Executive Officer)John Clarke(Executive Officer, Director)in
Co-investorsARCH Venture PartnersAvoro Capital AdvisorsCardinal PartnersNextech InvestSoftBank Vision FundAlexandria+4 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Aset TherapeuticsOyster Point PharmaceuticalsRespicardia
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.